Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

Pipelinepivots Aug. 15 at 1:19 AM

$PMNT $ICU $DFLI $ABOS $FLUX news today and upcoming catalysts watch 🚨TGL🚨 so quiet until its not Keep an eye on TGL crypto treasury theme micro float - $18 book value - CATALYSTS q3 Low shares to borrow & more

0 · Reply

winwithme Aug. 14 at 11:52 PM

Watchlist- $ICU $PMNT $DFLI $FLUX $ABOS

0 · Reply

CivilEngineer2444 Aug. 12 at 12:49 PM

$ABOS Investment Assessment Bullish Points Differentiated approach (oligomer-selective antibodies) could improve efficacy/safety profile vs. current marketed drugs. Strategic JCR partnership adds pipeline depth without significant near-term cash burn. Fully enrolled Phase 2 trial → execution risk on recruitment largely mitigated. Market tailwinds: expanding Alzheimer’s diagnostics, rising acceptance of disease-modifying therapies. Long cash runway into 2027 reduces dilution risk in near term. Upcoming Catalysts Early 2026 – Non-clinical data from JCR collaboration (decision on up to two candidates). Late 2026 – Top-line Phase 2 ALPITUDE AD results. Ongoing 2025–2026 – Industry readouts (Roche’s trodelvy brain shuttle, other amyloid/oligomer antibodies) may serve as sentiment drivers for Acumen’s approach. Bottom Line: Acumen (ABOS) has strong scientific rationale and strategic positioning in a high-growth Alzheimer’s market with potential differentiation in both efficacy and safety.

0 · Reply

redistributeW Aug. 12 at 11:08 AM

$ABOS burned 37 million? Late 2026 phase 2 results Really?

0 · Reply

stockstelegraph Aug. 12 at 9:18 AM

🚨 NASDAQ Earnings Before Open – Aug 12, 2025 🚨 💊 $ALMS – Alumis: EPS est. -1.11 (better than -1.82), $447M cap – biotech on watch 💉 $ALT – Altimmune: EPS est. -0.32, $274M cap – tightening losses 💻 $ALTS – ALT5 Sigma: Rev est. $5.9M, $115M cap – eyes on revenue beat 📈 $AGMH – AGM Group: EPS 0.66, $36.6M rev – profitable small-cap 🧠 $ABOS – Acumen Pharma: EPS -0.48 vs est. -0.54 – slight beat Which one’s your pre-market play? 👀📊 #Earnings #NASDAQ #Stocks

1 · Reply

CivilEngineer2444 Aug. 11 at 1:19 PM

$ABOS https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-report-second-quarter-2025-financial

0 · Reply

Aoi555 Aug. 4 at 11:01 AM

$ABOS If you are not a doctor, don't invest in medical stonks

0 · Reply

Okadarlan Aug. 1 at 5:48 PM

$ABOS made more then 50 % on this one at short @IjustTradeiT

0 · Reply

CivilEngineer2444 Jul. 31 at 2:12 PM

$ABOS is about to rip. Get in before its too late. Read the articles below.

0 · Reply

PeePeePantsCity Jul. 30 at 2:58 PM

$ABOS

0 · Reply

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 2 days ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:00 PM EDT - 9 days ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 4 weeks ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 5 weeks ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 13, 2025, 10:11 AM EDT - 3 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:00 PM EDT - 3 months ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 3 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 4 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 5 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 5 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 5 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 5 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Mar 10, 2025, 4:00 PM EDT - 5 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 26, 2024, 4:00 PM EST - 9 months ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 9 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 9 months ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 10 months ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 10 months ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 10 months ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 10 months ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 11 months ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 11 months ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 1 year ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 1 year ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 1 year ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 6, 2023, 4:01 PM EST - 1 year ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Nov 6, 2023, 7:30 AM EST - 1 year ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Pipelinepivots Aug. 15 at 1:19 AM

0 · Reply

winwithme Aug. 14 at 11:52 PM

Watchlist- $ICU $PMNT $DFLI $FLUX $ABOS

0 · Reply

CivilEngineer2444 Aug. 12 at 12:49 PM

0 · Reply

redistributeW Aug. 12 at 11:08 AM

$ABOS burned 37 million? Late 2026 phase 2 results Really?

0 · Reply

stockstelegraph Aug. 12 at 9:18 AM

1 · Reply

CivilEngineer2444 Aug. 11 at 1:19 PM

$ABOS https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-report-second-quarter-2025-financial

0 · Reply

Aoi555 Aug. 4 at 11:01 AM

$ABOS If you are not a doctor, don't invest in medical stonks

0 · Reply

Okadarlan Aug. 1 at 5:48 PM

$ABOS made more then 50 % on this one at short @IjustTradeiT

0 · Reply

CivilEngineer2444 Jul. 31 at 2:12 PM

$ABOS is about to rip. Get in before its too late. Read the articles below.

0 · Reply

PeePeePantsCity Jul. 30 at 2:58 PM

$ABOS

0 · Reply

CivilEngineer2444 Jul. 30 at 2:48 PM

$ABOS Operational innovation with the pTau217 assay could accelerate trial efficiency, reduce costs, and position sabirnetug competitively versus current AD therapeutics. The molecule’s high selectivity and biomarkers data, combined with Fast Track status, suggest strong potential for early medical uptake. Analyst enthusiasm and bullish price targets reflect upside expectations if Phase 2 data continue to deliver.

0 · Reply

ibaian Jul. 29 at 1:33 AM

$ABOS soon 🚀

0 · Reply

fredbull Jul. 28 at 12:33 PM

$ABOS this will be your next runner with great news $SMX $OPEN $CELC

0 · Reply

fredbull Jul. 28 at 12:29 PM

$ABOS https://www.globenewswire.com/news-release/2025/07/28/3122403/0/en/Acumen-Pharmaceuticals-Presents-Studies-Showing-the-Utility-of-a-pTau217-Assay-in-Screening-for-a-Phase-2-Alzheimer-s-Disease-Trial-and-Validates-Sabirnetug-Oligomer-Selectivity-at.html

0 · Reply

fredbull Jul. 28 at 12:27 PM

$ABOS this news has gone unnoticed. Very undervalued and oversold here $CRVO $CELC

0 · Reply

fredbull Jul. 28 at 12:18 PM

$ABOS this should be flying shortly

0 · Reply

Whiskey1679 Jul. 27 at 5:13 PM

Whiskeys Penny Stock Picks out tomorrow by 6:20 am PDT!! Trending: $COSM $APLS $ASND $ABOS $ANVS

1 · Reply

Johndoe456 Jul. 20 at 3:55 PM

$ABOS $CMPX I LIKE 💰

0 · Reply

Lofticus Jul. 15 at 4:26 PM

$ABOS

1 · Reply

bhavn008 Jul. 15 at 4:09 PM

$ABOS : Acumen Pharmaceuticals (NASDAQ: ABOS) announced a strategic deal with JCR Pharma today, to enhance brain delivery of its Alzheimer’s drug sabirnetug using J-Brain Cargo tech, with up to $555M in milestones and royalties. Sabirnetug, targeting toxic Aβ oligomers, is in Phase 2 (ALTITUDE-AD, enrolled March 2025, topline data late 2026) with low ARIA (7% in Phase 1) and strong target engagement. The deal addresses blood brain barrier, BBB limitations (only ~1% penetration for mAbs), de-risks pipeline, expands to next-gen variants, and provides non-dilutive funding amid $198M cash runway to 2027. Far from low confidence, it signals high belief in sabirnetug’s potential, strategic enhancement for better efficacy/safety in the $15B Alzheimer’s disease, AD market. Long ABOS. Not investment advice. #biotech #stocks #healthcare

1 · Reply

401stprophet Jul. 15 at 3:43 PM

$ABOS what are the thoughts on significant volume spike?

1 · Reply

CivilEngineer2444 Jul. 15 at 12:24 PM

$ABOS This is a materially positive development—providing a potential technical advantage and roadmap with multiple catalysts. Keep

0 · Reply

Market Cap	76.93M
Revenue (ttm)	0.00
Net Income (ttm)	-102.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	257,200
Avg Vol	518,146
Day's Range	N/A - N/A
Shares Out	60.57M
Stochastic %K	68%
Beta	0.14
Analysts	Strong Sell
Price Target	$7.80